Sign in
← Database
Metabolic Coenzyme

NAD+

Buy · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

An essential coenzyme at the centre of cellular energy metabolism and a substrate for sirtuins and DNA-repair enzymes. Levels decline with age; NAD+ and its precursors (NMN, NR) are studied for metabolic and ageing endpoints, and IV NAD+ is used off-label. It is not an approved therapeutic.

How it works

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every living cell relies on to move electrons during metabolism. It is essential to converting food into ATP — the cell's usable energy — through glycolysis, the citric-acid cycle, and the mitochondrial electron-transport chain.

NAD+ does more than energy: it is also consumed as a fuel by 'sirtuin' enzymes that influence gene expression and ageing pathways, and by PARP enzymes that repair DNA. Because cellular NAD+ tends to fall with age and metabolic stress, the idea behind taking NAD+ or its precursors is to top those pools back up.

NAD+ itself does not cross cell membranes well, so most supplementation uses precursors — nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) — that cells convert through the 'salvage' pathway; intravenous NAD+ is used off-label. Human outcome evidence is still developing, and it is not an approved therapeutic.

Mechanism · Detailed Analysis
Redox coenzymeCycles between NAD+ and NADH to shuttle electrons through glycolysis, the TCA cycle, and oxidative phosphorylation; the NAD+/NADH ratio governs metabolic flux.
Signaling substrateConsumed (not merely cycled) by NAD+-dependent enzymes — sirtuins (SIRT1–7) in deacetylation/ageing pathways, PARPs in DNA repair, and CD38 — linking NAD+ availability to stress and ageing responses.
Biosynthesis & salvageRegenerated mainly via the salvage pathway (nicotinamide → NMN by NAMPT, the rate-limiting step, → NAD+); de-novo synthesis from tryptophan is minor. The precursors NR and NMN feed this pathway.
Delivery & caveatsIntact NAD+ is poorly cell-permeable, so precursor strategies dominate; IV NAD+ is off-label. Clinical-outcome data remain early and it is not an approved therapeutic.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.